Literature DB >> 18559028

Conservative versus primary surgical treatment of acoustic neuromas: a comparison of rates of facial nerve and hearing preservation.

T P C Martin1, K Tzifa, C Kowalski, R L Holder, R Walsh, R M Irving.   

Abstract

OBJECTIVES: To determine whether patients with small to medium sized acoustic neuromas managed conservatively suffer reduced rates of facial nerve and hearing preservation when compared with patients undergoing primary surgery.
DESIGN: An intention-to-treat comparison between patients managed conservatively at first presentation and those managed with primary surgery.
SETTING: Tertiary referral neurotological centre in Birmingham, UK. PARTICIPANTS: Data were drawn from our database of 487 sporadic acoustic neuromas managed from 1997 to present day. MAIN OUTCOME MEASURES: Facial nerve status (assessed using the House-Brackmann system) was collated for all conservatively managed patients (n = 167) and compared with that expected when calculated from primarily surgically managed tumours of equivalent size (n = 121). A chi-square test was employed to test the statistical significance of any difference. Hearing preservation (maintenance of AAO-HNS Class) in patients presenting with Class A or B hearing was compared between conservatively managed patients and those with primary surgical management.
RESULTS: Observed facial nerve preservation in conservatively managed patients was significantly better (P < 0.001) than expected when calculated from rates of facial nerve preservation in surgically managed patients. Hearing preservation was also significantly more successful in conservatively managed patients (Pearson chi-square: P < 0.000).
CONCLUSIONS: An initial period of conservative management is a safe and reasonable management policy in all acoustic neuromas up to 2 cm in size at the cerebello-pontine angle. Given that there are no failsafe ways of deciding potential for growth in acoustic neuromas, initial conservative management of these tumours offers superior hearing and facial nerve preservation when compared with primary surgical treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18559028     DOI: 10.1111/j.1749-4486.2008.01715.x

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  6 in total

1.  Hearing in static unilateral vestibular schwannoma declines more than in the contralateral ear.

Authors:  Neel B Patel; Carrie L Nieman; Miriam Redleaf
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-01-13       Impact factor: 1.547

2.  Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience.

Authors:  Sumit Kapoor; Sachin Batra; Kathryn Carson; John Shuck; Siddharth Kharkar; Rahul Gandhi; Juan Jackson; Jan Wemmer; Stephanie Terezakis; Ori Shokek; Lawrence Kleinberg; Daniele Rigamonti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-29       Impact factor: 7.038

3.  Nonvestibulocochlear cranial nerve schwannomas.

Authors:  Luis J Mejico
Journal:  Curr Treat Options Neurol       Date:  2010-01       Impact factor: 3.598

Review 4.  What is the Required Frequency of MRI Scanning in the Wait and Scan Management?

Authors:  Thomas Somers; Romain Kania; Jerome Waterval; Tony Van Havenbergh
Journal:  J Int Adv Otol       Date:  2018-04       Impact factor: 1.017

5.  Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells.

Authors:  Nesrin Sabha; Karolyn Au; Sameer Agnihotri; Sanjay Singh; Rupinder Mangat; Abhijit Guha; Gelareh Zadeh
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

6.  Adherence to Long-Term Follow-up in Patients With Sporadic Vestibular Schwannomas Managed With Serial Observation.

Authors:  Mallory Raymond; Arian Ghanouni; Kaitlyn Brooks; Sarah M Clark; Douglas E Mattox
Journal:  OTO Open       Date:  2021-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.